Literature DB >> 11513911

In-vivo measurement of activated microglia in dementia.

A Cagnin1, D J Brooks, A M Kennedy, R N Gunn, R Myers, F E Turkheimer, T Jones, R B Banati.   

Abstract

BACKGROUND: Activated microglia have a key role in the brain's immune response to neuronal degeneration. The transition of microglia from the normal resting state to the activated state is associated with an increased expression of receptors known as peripheral benzodiazepine binding sites, which are abundant on cells of mononuclear phagocyte lineage. We used brain imaging to study expression of these sites in healthy individuals and patients with Alzheimer's disease.
METHODS: We studied 15 normal individuals (age 32-80 years), eight patients with Alzheimer's disease, and one patient with minimal cognitive impairment. Quantitative in-vivo measurements of glial activation were obtained with positron emission tomography (PET) and carbon-11-labelled (R)-PK11195, a specific ligand for the peripheral benzodiazepine binding site.
FINDINGS: In normal individuals, regional [11C](R)-PK11195 binding did not significantly change with age, except in the thalamus, where an age-dependent increase was found. By contrast, patients with Alzheimer's disease showed significantly increased regional [11C](R)-PK11195 binding in the entorhinal, temporoparietal, and cingulate cortex.
INTERPRETATION: In-vivo detection of increased [11C](R)-PK11195 binding in Alzheimer-type dementia, including mild and early forms, suggests that microglial activation is an early event in the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11513911     DOI: 10.1016/S0140-6736(01)05625-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  352 in total

1.  Lipolysaccharide-Induced Neuroinflammation Is Associated with Alzheimer-Like Amyloidogenic Axonal Pathology and Dendritic Degeneration in Rats.

Authors:  Xiaohua Deng; Meili Li; Weiming Ai; Lixin He; Dahua Lu; Peter R Patrylo; Huaibin Cai; Xuegang Luo; Zhiyuan Li; Xiaoxin Yan
Journal:  Adv Alzheimer Dis       Date:  2014-06

2.  Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?

Authors:  Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-15       Impact factor: 9.236

Review 3.  Applications of positron emission tomography (PET) in neurology.

Authors:  Y F Tai; P Piccini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

4.  Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission.

Authors:  Olivier Pascual; Sarrah Ben Achour; Philippe Rostaing; Antoine Triller; Alain Bessis
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-13       Impact factor: 11.205

Review 5.  Positron emission tomography imaging in neurological disorders.

Authors:  Marios Politis; Paola Piccini
Journal:  J Neurol       Date:  2012-09       Impact factor: 4.849

Review 6.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

Review 7.  In vivo PET imaging of neuroinflammation in Alzheimer's disease.

Authors:  Julien Lagarde; Marie Sarazin; Michel Bottlaender
Journal:  J Neural Transm (Vienna)       Date:  2017-05-17       Impact factor: 3.575

Review 8.  Glial adenosine kinase--a neuropathological marker of the epileptic brain.

Authors:  Eleonora Aronica; Ursula S Sandau; Anand Iyer; Detlev Boison
Journal:  Neurochem Int       Date:  2013-02-04       Impact factor: 3.921

9.  Aminopyrimidine Class Aggregation Inhibitor Effectively Blocks Aβ-Fibrinogen Interaction and Aβ-Induced Contact System Activation.

Authors:  Pradeep K Singh; Masanori Kawasaki; Hanna E Berk-Rauch; Goushi Nishida; Takeshi Yamasaki; Michael A Foley; Erin H Norris; Sidney Strickland; Kazuyoshi Aso; Hyung Jin Ahn
Journal:  Biochemistry       Date:  2018-02-09       Impact factor: 3.162

Review 10.  Sexual dimorphism in predisposition to Alzheimer's disease.

Authors:  Daniel W Fisher; David A Bennett; Hongxin Dong
Journal:  Neurobiol Aging       Date:  2018-04-17       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.